BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pihl AF, Feng S, Offersgaard A, Alzua GP, Augestad EH, Mathiesen CK, Jensen TB, Krarup H, Law M, Prentoe J, Christensen JP, Bukh J, Gottwein JM. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. J Hepatol 2022:S0168-8278(21)02303-5. [PMID: 34990750 DOI: 10.1016/j.jhep.2021.12.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sliepen K, Radić L, Capella-pujol J, Watanabe Y, Zon I, Chumbe A, Lee W, de Gast M, Koopsen J, Koekkoek S, del Moral-sánchez I, Brouwer PJM, Ravichandran R, Ozorowski G, King NP, Ward AB, van Gils MJ, Crispin M, Schinkel J, Sanders RW. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Nat Commun 2022;13:7271. [DOI: 10.1038/s41467-022-34961-8] [Reference Citation Analysis]
2 Feng T, Li M, Zhang L, Li S, Yang Z, Kang L, Guo Y, Kong L, Wang T. Immunity of two novel hepatitis C virus polyepitope vaccines. Vaccine 2022:S0264-410X(22)01115-X. [PMID: 36150975 DOI: 10.1016/j.vaccine.2022.09.020] [Reference Citation Analysis]
3 Alzua GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, Duan Z, Feng S, Fahnøe U, Sølund C, Weis N, Law M, Prentoe JC, Christensen JP, Bukh J, Gottwein JM. Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice. Gut 2022:gutjnl-2021-326323. [PMID: 35918103 DOI: 10.1136/gutjnl-2021-326323] [Reference Citation Analysis]